Acute hemolytic reaction in patients with novel coronavirus pneumonia induced by high-dose ribavirin injection: report of 2 cases
J. Gao, W. Qiao, Q. Xia, Q. Zhang
{"title":"Acute hemolytic reaction in patients with novel coronavirus pneumonia induced by high-dose ribavirin injection: report of 2 cases","authors":"J. Gao, W. Qiao, Q. Xia, Q. Zhang","doi":"10.3760/cma.j.cn114015-20200412-00518","DOIUrl":null,"url":null,"abstract":"Two female patients (patient 1, 22-year-old;patient 2, 50-year-old) received IV infusion of ribavirin injection (4 g in the first dose and the next day 1 2 g thrice daily), oral 2 lopinavir and ritonavir tablets twice daily, and aerosol inhalation of recombinant human interferon α2b for injection for novel coronavirus pneumonia There was no obvious abnormality in blood routine and liver function before treatment Laboratory tests showed red blood cell count (RBC) 2 89×1012/L, hemoglobin (Hb) 75 g/L, alanine aminotransferase (ALT) 22 8 U/L, aspartate aminotransferase (AST) 33 9 U/L, total bilirubin (TBil) 71 2 μmol/L, and indirect bilirubin (IBil) 63 5 μmol/L in patient 1 on the 2nd day of treatment, and RBC 3 46×1012/L, Hb 95 g/L, ALT 17 7 U/L, AST 21 3 U/L, TBil 86 1 μmol/L, and IBil 67 1 μmol/L in patient 2 on the 3rd day of treatment The direct antiglobulin test was positive, indirect antiglobulin test was negative, and antinuclear antibody test was negative in both patients They were diagnosed as having acute hemolytic anemia Con-sidering the relationship to ribavirin, ribavirin was given in reduced dose and then finally discontinued in patient 1, and was discontinued directly in patient 2 On the basis of continued use of the other 2 drugs, both of them were treated with ursodeoxycholic acid The Hb and bilirubin level of the 2 patients gradually returned to normal Copyright © 2020 by the Chinese Medical Association","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":"4 1","pages":"547-549"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20200412-00518","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Two female patients (patient 1, 22-year-old;patient 2, 50-year-old) received IV infusion of ribavirin injection (4 g in the first dose and the next day 1 2 g thrice daily), oral 2 lopinavir and ritonavir tablets twice daily, and aerosol inhalation of recombinant human interferon α2b for injection for novel coronavirus pneumonia There was no obvious abnormality in blood routine and liver function before treatment Laboratory tests showed red blood cell count (RBC) 2 89×1012/L, hemoglobin (Hb) 75 g/L, alanine aminotransferase (ALT) 22 8 U/L, aspartate aminotransferase (AST) 33 9 U/L, total bilirubin (TBil) 71 2 μmol/L, and indirect bilirubin (IBil) 63 5 μmol/L in patient 1 on the 2nd day of treatment, and RBC 3 46×1012/L, Hb 95 g/L, ALT 17 7 U/L, AST 21 3 U/L, TBil 86 1 μmol/L, and IBil 67 1 μmol/L in patient 2 on the 3rd day of treatment The direct antiglobulin test was positive, indirect antiglobulin test was negative, and antinuclear antibody test was negative in both patients They were diagnosed as having acute hemolytic anemia Con-sidering the relationship to ribavirin, ribavirin was given in reduced dose and then finally discontinued in patient 1, and was discontinued directly in patient 2 On the basis of continued use of the other 2 drugs, both of them were treated with ursodeoxycholic acid The Hb and bilirubin level of the 2 patients gradually returned to normal Copyright © 2020 by the Chinese Medical Association
大剂量利巴韦林注射液致新型冠状病毒肺炎患者急性溶血反应2例报告
2例女性患者(患者1,22岁;患者2,50岁)静脉滴注利巴韦林注射液(首剂4 g,次日12 g,每日3次),口服洛匹那韦、利托那韦片2片,每日2次,雾化吸入注射用重组人α2b干扰素治疗新型冠状病毒肺炎。治疗前血常规、肝功能未见明显异常,实验室检查红细胞计数2 89×1012/L;血红蛋白(Hb) 75 g / L,丙氨酸转氨酶(ALT) 22日8 U / L天冬氨酸转氨酶(AST) 33 9 U / L,总胆红素(治疗组)71 2μmol / L, 63 5μ、间接胆红素(IBil)病人1 mol / L的第二天治疗,46和加拿大皇家银行3×1012 / L, Hb 95 g / L, 17 7 U / L, ALT AST 21 3 U / L,治疗组1μmol / L, 86和67年IBil 1μmol / L的病人2治疗的第三天直接抗球蛋白试验是积极的,间接抗球蛋白试验是负数,考虑到与利巴韦林的关系,患者1减量停用利巴韦林,患者2在继续使用其他2种药物的基础上直接停用利巴韦林。2例患者均给予熊去氧胆酸治疗,Hb、胆红素水平逐渐恢复正常著作权©中华医学会2020
本文章由计算机程序翻译,如有差异,请以英文原文为准。